Ekso Bionics Holdings, Inc.
NASDAQ:EKSO
1.225 (USD) • At close September 13, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 18.279 | 12.912 | 11.246 | 8.882 | 13.917 | 11.332 | 7.353 | 14.221 | 8.661 | 5.327 | 3.302 | 2.706 |
| Cost of Revenue
| 8.581 | 6.698 | 4.497 | 3.812 | 7.153 | 7.023 | 5.284 | 11.274 | 7.482 | 3.768 | 2.715 | 2.336 |
| Gross Profit
| 9.698 | 6.214 | 6.749 | 5.07 | 6.764 | 4.309 | 2.069 | 2.947 | 1.179 | 1.559 | 0.587 | 0.37 |
| Gross Profit Ratio
| 0.531 | 0.481 | 0.6 | 0.571 | 0.486 | 0.38 | 0.281 | 0.207 | 0.136 | 0.293 | 0.178 | 0.137 |
| Reseach & Development Expenses
| 5.025 | 3.626 | 2.748 | 2.474 | 4.596 | 5.847 | 9.483 | 8.879 | 6.48 | 3.868 | 3.931 | 6.087 |
| General & Administrative Expenses
| 10.694 | 10.987 | 10.524 | 7.702 | 7.409 | 11.7 | 10.715 | 10.853 | 7.002 | 7.4 | 0.011 | 4.381 |
| Selling & Marketing Expenses
| 8.472 | 7.157 | 7.305 | 7.752 | 11.398 | 13.827 | 13.156 | 10.997 | 9.258 | 7.085 | 4.291 | 5.926 |
| SG&A
| 19.166 | 18.144 | 17.829 | 15.454 | 18.807 | 25.527 | 23.871 | 21.85 | 16.26 | 14.485 | 0.011 | 10.307 |
| Other Expenses
| -0.619 | -0.03 | -0.884 | 0.99 | -0.132 | -0.425 | 0.296 | -0.166 | -0.045 | -0.061 | 0.001 | 0.001 |
| Operating Expenses
| 24.81 | 21.77 | 20.577 | 17.928 | 23.403 | 31.374 | 33.354 | 30.729 | 22.74 | 18.353 | 0.011 | 14.687 |
| Operating Income
| -15.112 | -15.556 | -13.828 | -12.858 | -16.639 | -27.03 | -31.612 | -27.586 | -21.561 | -16.794 | -0.012 | -14.241 |
| Operating Income Ratio
| -0.827 | -1.205 | -1.23 | -1.448 | -1.196 | -2.385 | -4.299 | -1.94 | -2.489 | -3.153 | -0.004 | -5.263 |
| Total Other Income Expenses Net
| -0.086 | 0.476 | 4.064 | -2.967 | 4.507 | 0.673 | 2.811 | 4.482 | 1.973 | -16.546 | -0.001 | -0.801 |
| Income Before Tax
| -15.198 | -15.08 | -9.764 | -15.825 | -12.132 | -26.992 | -29.122 | -23.47 | -19.59 | -33.769 | -0.012 | -15.042 |
| Income Before Tax Ratio
| -0.831 | -1.168 | -0.868 | -1.782 | -0.872 | -2.382 | -3.961 | -1.65 | -2.262 | -6.339 | -0.004 | -5.559 |
| Income Tax Expense
| 1.53 | -0.476 | -1.332 | 1.129 | -0.438 | 1.273 | 0.944 | -6.167 | -0.965 | -0.371 | -0.001 | 0 |
| Net Income
| -15.198 | -14.604 | -8.432 | -16.954 | -11.694 | -26.992 | -29.122 | -23.47 | -19.59 | -33.769 | -0.012 | -15.042 |
| Net Income Ratio
| -0.831 | -1.131 | -0.75 | -1.909 | -0.84 | -2.382 | -3.961 | -1.65 | -2.262 | -6.339 | -0.004 | -5.559 |
| EPS
| -1.1 | -1.13 | -0.69 | -2.37 | -2.44 | -6.61 | -12.27 | -19.42 | -15.53 | -34.96 | -0.045 | -4.03 |
| EPS Diluted
| -1.1 | -1.13 | -0.69 | -2.37 | -2.44 | -6.61 | -12.27 | -18.9 | -15.52 | -34.96 | -0.045 | -4.03 |
| EBITDA
| -13.414 | -15.586 | -14.712 | -11.577 | -17.867 | -27.49 | -29.257 | -32.264 | -21.595 | -16.849 | -0.011 | -13.899 |
| EBITDA Ratio
| -0.734 | -1.207 | -1.308 | -1.303 | -1.284 | -2.426 | -3.979 | -2.269 | -2.493 | -3.163 | -0.003 | -5.136 |